AstraZeneca charts new course for Imfinzi in liver cancer, but FDA path remains uncertain
AstraZeneca charts new course for Imfinzi in liver cancer, but FDA path remains uncertain aliu Thu, 01/18/2024 - 14:27
AstraZeneca charts new course for Imfinzi in liver cancer, but FDA path remains uncertain aliu Thu, 01/18/2024 - 14:27
After Pfizer offers discount, NICE gives thumbs up to breast cancer drug Talzenna kdunleavy Thu, 01/18/2024 - 13:33
With manufacturing-related rejection, FDA turns its nose up at Satsuma's migraine nasal spray zbecker Thu, 01/18/2024 - 10:58
Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors aliu Thu, 01/18/2024 - 10:34
After 17-year courtship, Sun and Taro finally agree on $348M buyout kdunleavy Thu, 01/18/2024 - 10:08
AstraZeneca to drop $26.5M in China for new production line for diabetes drugs: report jkeenan Thu, 01/18/2024 - 08:20
Bayer CEO Bill Anderson makes his mark with major restructuring, 'significant' job cuts aliu Wed, 01/17/2024 - 18:23